Q2 Earnings Estimate for KROS Issued By Leerink Partnrs

Keros Therapeutics, Inc. (NASDAQ:KROS) – Equities researchers at Leerink Partnrs issued their Q2 2025 earnings per share (EPS) estimates for Keros Therapeutics in a research note issued to investors on Thursday, February 27th. Leerink Partnrs analyst T. Smith forecasts that the company will earn ($1.02) per share for the quarter. The consensus estimate for Keros Therapeutics’ current full-year earnings is ($4.74) per share. Leerink Partnrs also issued estimates for Keros Therapeutics’ Q3 2025 earnings at ($0.66) EPS and Q4 2025 earnings at ($0.63) EPS.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings data on Wednesday, February 26th. The company reported ($1.14) EPS for the quarter, beating analysts’ consensus estimates of ($1.36) by $0.22. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The company had revenue of $3.04 million for the quarter, compared to analyst estimates of $37.32 million.

Other equities research analysts have also issued research reports about the company. BTIG Research lowered Keros Therapeutics from a “buy” rating to a “neutral” rating in a research report on Thursday, December 12th. Piper Sandler cut their price target on Keros Therapeutics from $40.00 to $15.00 and set an “overweight” rating on the stock in a report on Friday, January 17th. Wedbush downgraded shares of Keros Therapeutics from an “outperform” rating to a “neutral” rating and reduced their price objective for the stock from $47.00 to $15.00 in a research report on Friday, January 17th. HC Wainwright dropped their target price on shares of Keros Therapeutics from $47.00 to $40.00 and set a “buy” rating on the stock in a research report on Thursday. Finally, William Blair cut shares of Keros Therapeutics from an “outperform” rating to a “market perform” rating in a report on Thursday, December 12th. Six investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, Keros Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $42.33.

Keros Therapeutics Trading Up 0.6 %

Shares of KROS opened at $11.01 on Friday. The firm’s fifty day simple moving average is $12.64 and its two-hundred day simple moving average is $39.79. Keros Therapeutics has a 12 month low of $9.77 and a 12 month high of $73.00. The stock has a market capitalization of $445.98 million, a P/E ratio of -2.11 and a beta of 1.39.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in KROS. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Keros Therapeutics by 26.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock valued at $77,000 after acquiring an additional 280 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its stake in Keros Therapeutics by 70.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,217 shares of the company’s stock valued at $419,000 after purchasing an additional 2,978 shares during the period. Emerald Mutual Fund Advisers Trust purchased a new stake in shares of Keros Therapeutics during the 3rd quarter valued at $6,539,000. Emerald Advisers LLC purchased a new stake in shares of Keros Therapeutics during the 3rd quarter valued at $9,032,000. Finally, AlphaCentric Advisors LLC bought a new stake in shares of Keros Therapeutics during the 3rd quarter worth $465,000. 71.56% of the stock is owned by institutional investors.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.